| Identification | Back Directory | [Name]
(5Z)-7-[(1α,4α)-3β-[(1E,3S)-3-Hydroxy-1-octenyl]-7-oxabicyclo[2.2.1]heptane-2α-yl]-5-heptenoic acid | [CAS]
82337-14-2 | [Synonyms]
SQ-26655
(5Z,8R,9S,11R,13E,15S)-9a-Homo-9,11-epoxy-15-hydroxyprosta-5,13-dienoic acid
(Z)-7-[(1S,4R)-3β-[(1E,3S)-3-Hydroxy-1-octenyl]-7-oxabicyclo[2.2.1]heptan-2α-yl]-5-heptenoic acid
(5Z)-7-[(1α,4α)-3β-[(1E,3S)-3-Hydroxy-1-octenyl]-7-oxabicyclo[2.2.1]heptane-2α-yl]-5-heptenoic acid
(5Z)-7-[(1S,1α,4α)-3β-[(3S,1E)-3-Hydroxy-1-octene-1-yl]-7-oxabicyclo[2.2.1]heptane-2α-yl]-5-heptenoic acid | [Molecular Formula]
C21H34O4 | [MOL File]
82337-14-2.mol | [Molecular Weight]
350.492 |
| Hazard Information | Back Directory | [Description]
SQ 26655 is a thromboxane A2/prostaglandin H2 antagonist. | [Uses]
SQ 26655 is a TxA2 receptor agonist. SQ 26655 induces human platelet aggregation[1]. | [References]
[1] Harris DN, et al. Effects of SQ 27,427, a thromboxane A2 receptor antagonist, in the human platelet and isolated smooth muscle. Eur J Pharmacol. 1984 Aug 3;103(1-2):9-18. DOI:10.1016/0014-2999(84)90183-3 |
|
|